- Augmenta Bioworks and TFF Pharmaceuticals Inc TFFP have selected AUG-3387 as the first lead monoclonal antibody for clinical development against COVID-19 under their joint development Collaboration Agreement.
- AUG-3387 will be developed as an inhaled therapy for the treatment of COVID-19 disease.
- Notably, in in vitro preclinical testing, AUG-3387 effectively neutralizes SARS-CoV2 and has demonstrated activity against all variant strains tested to date.
- TFF and Augmenta have an ongoing commitment to monitor the activity of AUG-3387 against emerging variants and will be completing in vivo preclinical efficacy studies in the coming weeks.
- Price Action: TFFP shares are down 2.98% at $10.09 during the market trading session on the last check Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
